A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses

Cancer

Volumn 80, Issue 12, 1997, Pages 2222-2229

  Tummarello, Diego ^a   Mari, Davide ^a   Graziano, Francesco ^a   Isidori, Pierpaolo ^c   Cetto, Gianluigi ^b   Pasini, Felice ^b   Santo, Antonio ^b   Cellerino, Riccardo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Chemoimmunotherapy; Interferon; Maintenance therapy; Phase III trial; Podophillotoxins; Small cell lung carcinoma; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT ALPHA2B INTERFERON; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INTERFERON ALFA-2B; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0031467621     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971215)80:12<2222::AID-CNCR2>3.0.CO;2-W     Document Type: Article

References (30)

1. Seifert EJ, Ihde DC. Therapy of small-cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988;15:278-99.
2. Hide DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
3. Einhorn LH, Pennington K, McClean J. Phase II trial of oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1990;17:32-5.
4. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 1992;19:36-9.
5. Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH. Teniposide (VM 26), an overlooked highly active agent in small cell lung cancer: results of a phase II trial in untreated patients. J Clin Oncol 1986;4:524-7.
6. Tummarello D, Isidori P, Pasini F, Cetto G, Cellerino R. Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. Eur J Cancer 1992;28A:1081-4.
7. Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, et al. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 1989;7:450-6.
8. Jett JR, Everson L, Therneau TM, Krook JE, Dalton RJ, Marschke RF, et al. Treatment of limited-stage small cell lung cancer with cyclophosphamide, doxorubicin and vincristine with or without etoposide: a randomized study of the North Central Cancer Treatment Group. J Clin Oncol 1990;8:33-9.
9. Jackson DV, Case LD, Zekan PJ, Powell BL, Caldwell RD, Bearden JD, et al. Improvement of long-term survival in extensive small cell lung cancer. J Clin Oncol 1988;6:1161-9.
10. Colombo T, Broggini M, Vaghi M, Amato G, Erba E, D'Incalchi M. Comparison between VP16 and VM26 in Lewis lung carcinoma of the mouse. Eur J Cancer Clin Oncol 1986;22:173-9.
11. Matsushima Y, Kanazawa F, Miyzawa N, Sasaki Y, Saijo NL. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay. Anticancer Res 1986;6:921-4.
12. Giaccone G, Donadio M, Bonardi M, Testore F, Galbiati A. Teniposide in treatment of small cell lung cancer: the influence of prior therapy. J Clin Oncol 1988;8:1264-70.
13. Bork E, Ersboll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol 1991;9:1627-31.
14. Tummarello D, Guidi F, Torresi U, Dazzi C, Cellerino R. Teniposide (VM26) as second-line treatment for small cell lung cancer. Anticancer Res 1990;10:397-400.
15. Mattson K, Niiranen A, Pyrhonen S, Holsti LR, Kumpulainen E, Cantell K. Natural interferon alpha as maintenance therapy for small cell lung cancer. Eur J Cancer 1992;8:1387-91.
16. Kelly K, Bunn PA, Hazuka M, Beasley K, Crowley J, Livingstone R. The role of alpha interferon (rIFN a-2a) maintenance in patients with limited stage small cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study (SWOG). Proc Am Soc Clin Oncol 1993;12:330.
17. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, et al. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J Clin Oncol 1994;12:2321-6.
18. Glisson BS, Palmer JL, Shin DM, Wester M, Markowitz AB. Phase II trial of interferon alpha (IFN) plus etoposide/cisplatin (EP) induction and IFN/Megace (M) maintenance in extensive small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 1993;12:354.
19. Bitran JD, Green M, Perry M, Hollis DR. A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. Am J Clin Oncol 1995;18:67-70.
20. Balkwill FR, Smyth JF. Interferons in cancer therapy: a reappraisal. Lancet 1987;2:317-9.
21. Hussain A, Yen R, Borges M, et al. Expression and methylation patterns of class I MHC antigen genes in small cell lung cancer and non-small cell lung cancer. Proc Am Assoc Cancer Res 1987;28:349.
22. Pujol JL, Gibney DJ, Su JQ, Maksymiuk AW, Jett JR. Immune response induced in small cell lung cancer by maintenance therapy with interferon. J Natl Cancer Inst 1993;85:1844-50.
23. Abrams J, Doyle LA, Aisner J. Staging prognostic features, and special considerations in small-cell lung cancer. Semin Oncol 1988;15:261-77.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
25. Tonkin K, Tritchler D, Tannock I. Criteria of tumor response used in clinical trials of chemotherapy. J Clin Oncol 1985;3:870-5.
26. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chron Dis 1974;27:15-24.
27. Tummarello D, Mari D, Graziano F, Cetto G, Pasini F, Antonio S, et al. Small cell lung cancer (SCLC): a randomized trial of cytoxan, adriamycin plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment as maintenance therapy. Anticancer Res 1994;14:2221-8.
28. Cherney T, Perazzini A, Joss RA. Unexpected high toxicity in a phase II study of teniposide (VM26) in elderly patients with untreated small cell lung cancer (SCLC). Eur J Cancer Clin Oncol 1988;24:1791-4.
29. Kohne-Wompner CH, Koschel G, Pawel JV, Wilke H, Vallee D, Bremer K, et al. Small-cell lung cancer (SCLC) limited disease (LD): carboplatin (C), etoposide (E), vincristine (V) chemotherapy (CT) and radiotherapy (RT) followed by a-2b interferon (IFN) maintenance vs observation for patients (pts) with response after CT/RT. Ann Oncol 1992;(S3):40.
30. Van Zandwijk N, Groen HJM, Postmus PE, Burghouts JTW, Ten Velde GPM, Ardizzoni A, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer: a randomized phase III study of the EORTC Lung Cancer Cooperative Group. In press.